Boehringer Ingelheim and Dassault Systèmes subsidiary Medidata have expanded their partnership by five years for the latter’s Rave electronic data capture (EDC) in clinical trials.
Rave EDC will be used in the trials of Boehringer globally.
The deal includes Medidata’s myMedidata, which is a suite of patient-facing technologies to boost participant centricity and diversity in decentralised clinical trials (DCTs).
By offering the scalable patient-centred expertise of Medidata, the deal will strengthen Boehringer’s focus on engaging patients in a meaningful manner.
This comprises a one-destination web-based platform, myMedidata patient portal, which offers access to electronic consent, electronic Clinical Outcome Assessment (eCOA), and myMedidata LIVE video investigator/patient visits.
An end-to-end offering, the Medidata Decentralized Clinical Trials Program is claimed to be aiding in transforming how people offer data, how drugs are dispatched to patients, and how trial data is managed and examined.
These remote technologies offer opportunities to boost patient access, inclusion, and engagement across various regions and enhance the diversity of patients in trials.
Apart from Rave EDC, Boehringer has built on the technologies of Medidata including Coder, targeted source data verification (TSDV), and Safety Gateway.
Boehringer is also analysing Medidata AI Intelligent Trials to offer improved analytics to boost the trial’s pace, success, and quality.
Medidata Patient Cloud CEO Anthony Costello said: “Boehringer Ingelheim’s global reach across therapeutic areas is a perfect match for the scalable capabilities of myMedidata and the rest of the Medidata Clinical Cloud platform.
“Together, we will be able to quickly improve access and diversity of participation in a wide range of clinical programmes.”
The latest development comes after Medidata unveiled the new Intelligent Trials Diversity Module which will aid sponsors and clinical research organisations to boost trial diversity and inclusion.